Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Biofrontera Inc. (BFRI : NSDQ)

• Company Description    Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Biofrontera Inc. is based in WOBURN, MA. Number of Employees: 94

• Price / Volume Information    Yesterday's Closing Price: $0.81 Daily Weekly Monthly 20 Day Moving Average: 269,502 shares Shares Outstanding: 12.80 (millions) Market Capitalization: $10.34 (millions) Beta: 0.89 52 Week High: $1.19 52 Week Low: $0.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.62% -25.45% 12 Week -12.89% -19.47% Year To Date 41.63% 25.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 660 Main Street 1st Floor - WOBURN,MA 01801 USA ph: 781-245-1325 fax: - ir@bfinc.com http://www.biofrontera.us.com

• General Corporate Information    Officers Hermann Lubbert - Chief Executive Officer and Chairman E. Fred Leffler - Chief Financial Officer Beth J. Hoffman - Director Heikki Lanckriet - Director Heikki Lanckriet - Director Peer Information Biofrontera Inc. (CORR.) Biofrontera Inc. (RSPI) Biofrontera Inc. (CGXP) Biofrontera Inc. (BGEN) Biofrontera Inc. (GTBP) Biofrontera Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09077D209 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 12.80 Most Recent Split Date: 7.00 (0.05:1) Beta: 0.89 Market Capitalization: $10.34 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.30 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.70 Price/Cash Flow: - Price / Sales: 0.24 EPS Growth vs. Year Ago Period: 12.77% vs. Previous Quarter: -182.00% Sales Growth vs. Year Ago Period: 17.42% vs. Previous Quarter: -41.03% ROE 03/31/26 - -515.34 12/31/25 - -1,236.11 09/30/25 - - ROA 03/31/26 - -53.91 12/31/25 - -56.67 09/30/25 - -93.14 Current Ratio 03/31/26 - 1.20 12/31/25 - 1.52 09/30/25 - 1.15 Quick Ratio 03/31/26 - 1.09 12/31/25 - 1.40 09/30/25 - 0.80 Operating Margin 03/31/26 - -27.74 12/31/25 - -27.42 09/30/25 - -46.52 Net Margin 03/31/26 - -25.66 12/31/25 - -25.26 09/30/25 - -47.28 Pre-Tax Margin 03/31/26 - -25.60 12/31/25 - -25.20 09/30/25 - -47.22 Book Value 03/31/26 - 0.47 12/31/25 - 0.90 09/30/25 - -0.22 Inventory Turnover 03/31/26 - 3.56 12/31/25 - 2.69 09/30/25 - 2.46 Debt-to-Equity 03/31/26 - 0.78 12/31/25 - 0.44 09/30/25 - - Debt-to-Capital 03/31/26 - 43.74 12/31/25 - 30.45 09/30/25 - -

Powered by Zacks Investment Research ©